| Entry |
|
| Name |
Mutation-activated RET to PI3K signaling pathway
|
| Definition |
RET* -> PI3K -> PIP3 -> AKT -> MTOR |
| Expanded |
5979v2 -> (5290,5291,5293) -> C05981 -> (207,208,10000) -> 2475 |
| Class |
|
| Type |
Variant
|
| Disease |
|
| Gene |
| 5979 | RET; ret proto-oncogene |
| 5290 | PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha |
| 5291 | PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta |
| 5293 | PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta |
| 207 | AKT1; AKT serine/threonine kinase 1 |
| 208 | AKT2; AKT serine/threonine kinase 2 |
| 10000 | AKT3; AKT serine/threonine kinase 3 |
| 2475 | MTOR; mechanistic target of rapamycin kinase |
|
| Variant |
|
| Metabolite |
| C05981 | Phosphatidylinositol-3,4,5-trisphosphate |
|
| Reference |
|
| Authors |
Giunti S, Antonelli A, Amorosi A, Santarpia L |
| Title |
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. |
| Journal |
|
| Reference |
|
| Authors |
Ceolin L, Duval MADS, Benini AF, Ferreira CV, Maia AL |
| Title |
Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives. |
| Journal |
|
| Reference |
|
| Authors |
Arighi E, Borrello MG, Sariola H |
| Title |
RET tyrosine kinase signaling in development and cancer. |
| Journal |
|
| LinkDB |
|